More from the company: RhoVac AB strengthens project coordination and communication

Press release from Companies: Positive immune monitoring results have been demonstrated with the company's cancer vaccine RV001

Press release from Companies: Positivt immunmonitoreringsresultat har påvisats med bolagets cancervaccin RV001

Press release from Companies: RhoVac AB is expanding its internationalpresence by attending conferences and by increasing activity on digital media

Press release from Companies: RhoVac AB is expanding its internationalpresence by attending conferences and by increasing activity on digital media

More from the company: RhoVac AB utökar dess internationella närvaro genom att delta ikonferenser och öka aktiviteten i digitala medier

More from the company: RhoVac AB announces that the first patient in the company's clinical phase I/II study has now completed the treatment phase with cancer vaccine RV001

More from the company: RhoVac AB announces that the first patient in the company's clinical phase I/II study has now completed the treatment phase with cancer vaccine RV001

More from the company: RhoVac AB informerar om att första patienten i bolagets kliniska fas I/II-studie nu har avslutat behandlingsfasen med RV001

More from the company: RhoVac AB informerar om att första patienten i bolagets kliniska fas I/II-studie nu har avslutat behandlingsfasen med RV001

Reports: Delårsrapport Januari - September 2017

More from the company: RhoVac AB presenterar på Investival Showcase i London och Sedermeradagen i Stockholm